









Mercado
/
Acciones
/
nasdaq-rnac
/

Cartesian Therapeutics Inc

RNAC

10.310USD

+1.160+12.68%

Cierre 09/18, 16:00（ET）Cotizaciones retrasadas 15 min

268.06MCap. mercado

PérdidaP/E TTM



Cartesian Therapeutics Inc

10.310

+1.160+12.68%

Descripción general Compañía Finanzas Análisis

Análisis

Más Datos de Cartesian Therapeutics Inc Compañía

Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Información de la empresa

Símbolo de cotizaciónRNAC

Nombre de la empresaCartesian Therapeutics Inc

Fecha de salida a bolsaJun 22, 2016

Director ejecutivoDr. Carsten Brunn, Ph.D.

Número de empleados66

Tipo de seguridadOrdinary Share

Fin del año fiscalJun 22

Dirección7495 New Horizon Way

CiudadFREDERICK

Bolsa de valoresNASDAQ Global Market Consolidated

PaísUnited States of America

Código postal21703

Teléfono13013488698

Sitio Webhttps://www.cartesiantherapeutics.com/

Símbolo de cotizaciónRNAC

Fecha de salida a bolsaJun 22, 2016

Director ejecutivoDr. Carsten Brunn, Ph.D.

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Murat Kalayoglu, M.D., Ph.D.

Independent Director

502.42K

-1.74%

Dr. Emily English, Ph.D.

Chief Operations Officer

36.95K

+25.46%

Dr. Carsten Brunn, Ph.D.

President, Chief Executive Officer, Director

30.24K

-38.23%

Dr. Milos Miljkovic, M.D.

Chief Medical Officer

17.12K

Mr. Blaine Davis

Chief Financial Officer

12.21K

-87.12%

Mr. Patrick J. (Pat) Zenner

Independent Director

3.82K

-14.03%

Dr. Kemal Malik

Independent Director

-100.00%

Dr. Michael S. Singer, M.D., Ph.D.

Independent Director

Mr. Timothy C. (Tim) Barabe

Independent Director

Dr. Nishan M. de Silva, M.D.

Independent Director

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Murat Kalayoglu, M.D., Ph.D.

Independent Director

502.42K

-1.74%

Dr. Emily English, Ph.D.

Chief Operations Officer

36.95K

+25.46%

Dr. Carsten Brunn, Ph.D.

President, Chief Executive Officer, Director

30.24K

-38.23%

Dr. Milos Miljkovic, M.D.

Chief Medical Officer

17.12K

Mr. Blaine Davis

Chief Financial Officer

12.21K

-87.12%

Mr. Patrick J. (Pat) Zenner

Independent Director

3.82K

-14.03%

Desglose de ingresos

Sin datos

Sin datos

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: jue., 14 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

Springer Timothy A

33.22%

Seven One Eight Three Four Irrevocable Trust

17.52%

Fidelity Management & Research Company LLC

8.98%

Singer (Michael S.)

2.72%

MPM BioImpact LLC

2.64%

Otro

34.93%

Accionistas

Proporción

Springer Timothy A

33.22%

Seven One Eight Three Four Irrevocable Trust

17.52%

Fidelity Management & Research Company LLC

8.98%

Singer (Michael S.)

2.72%

MPM BioImpact LLC

2.64%

Otro

34.93%

Tipos de accionistas

Accionistas

Proporción

Individual Investor

39.87%

Corporation

20.04%

Investment Advisor

17.88%

Investment Advisor/Hedge Fund

5.50%

Hedge Fund

1.66%

Research Firm

0.24%

Insurance Company

0.08%

Bank and Trust

0.05%

Pension Fund

0.03%

Otro

14.64%

Participación institucional

Actualizado: mar., 1 de jul

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q2

206

22.27M

85.81%

-1.28M

2025Q1

226

22.94M

90.08%

+138.68K

2024Q4

230

22.26M

88.90%

-105.22K

2024Q3

229

20.22M

92.77%

+6.58M

2024Q2

235

14.41M

85.20%

+9.02M

2024Q1

233

3.74M

346.71%

-1.42M

2023Q4

240

3.82M

71.00%

-922.87K

2023Q3

251

3.63M

70.60%

-1.17M

2023Q2

261

3.72M

72.70%

-649.68K

2023Q1

272

3.43M

67.38%

-196.84K

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Springer Timothy A

8.64M

33.28%

+22.36K

+0.26%

Apr 14, 2025

Seven One Eight Three Four Irrevocable Trust

4.56M

17.55%

Apr 14, 2025

Fidelity Management & Research Company LLC

2.34M

9.02%

-83.30K

-3.44%

Mar 31, 2025

Singer (Michael S.)

707.06K

2.72%

-623.00

-0.09%

Apr 14, 2025

MPM BioImpact LLC

790.78K

3.05%

+69.64K

+9.66%

Mar 31, 2025

TAS Partners, L.L.C.

656.51K

2.53%

+126.72K

+23.92%

Apr 14, 2025

BlackRock Institutional Trust Company, N.A.

608.03K

2.34%

+1.49K

+0.25%

Mar 31, 2025

Invus Public Equities Advisors, LLC

563.27K

2.17%

-8.96K

-1.57%

Mar 31, 2025

Kalayoglu (Murat)

502.42K

1.94%

-8.88K

-1.74%

Apr 14, 2025

The Vanguard Group, Inc.

503.54K

1.94%

+74.06K

+17.24%

Mar 31, 2025

ETFs relacionados

Nombre

Proporción

Sin datos

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones

Fecha

Tipo

Relación

Mar 28, 2024

Merger

30→1

Mar 28, 2024

Merger

30→1

Mar 28, 2024

Merger

30→1

Mar 28, 2024

Merger

30→1

Fecha

Tipo

Relación

Mar 28, 2024

Merger

30→1

Mar 28, 2024

Merger

30→1

Mar 28, 2024

Merger

30→1

Mar 28, 2024

Merger

30→1

KeyAI

